Patent · US Active

Nucleoside phosphoramidate compound and use thereof

US9963480B2 · kind B2 · utility

0Cited by

3References

18Claims

0Family size

Assignee

NANJING SANHOME PHARMACEUTICAL CO., LTD. · CN

Inventors

Yong Wang · 安丰镇, CN
Liwen ZHAO · 安丰镇, CN
Xian Zhang · Beijing, CN
Sheng Bi · 安丰镇, CN
Yiping Gao · Nanjing, CN
Hongyan Chen · 安丰镇, CN
Dezhong Wang · Nanjing, CN
Yang Nan · Nanjing, CN
Cang Zhang · Nanjing, CN
Yuxiu Li · Nanjing, CN
Di Zhang · Xing'an, CN

Key dates

Filing date	Mar 6, 2014
Grant date	May 8, 2018
Priority date	—
Expiry date	Aug 27, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P31/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A novel nucleoside phosphoramidate compound of the formula below, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection, and having a good anti-HCV effect; a pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.